Dabigatran-Reversal Agent Price Set

By Joe Elia

Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD

Idarucizumab (Praxbind), an agent just approved by the FDA to reverse the anticoagulant effects of dabigatran (Pradaxa), will be available for a "US wholesale acquisition cost ... of $3,500," a Boehringer-Ingelheim official has told Physician's First Watch.

Lauren Murphy wrote in an email that the price "has been set to help ensure the likelihood that [idarucizumab] can be available at institutions where [dabigatran] patients seek emergency care."